Glaucoma treatment focus of Novartis deal

December 15, 2005

Basel, Switzerland—Novartis will work with Senju Pharmaceutical Co. to develop and commercialize a topical treatment for glaucoma.

Basel, Switzerland-Novartis will work with Senju Pharmaceutical Co. to develop and commercialize a topical treatment for glaucoma.

The deal involves Y39983, a rho kinase inhibitor, under sub-license rights granted to Senju by Mitsubishi Pharma Corp.